Skip to content
10-Q

Quarterly Report

Enliven Therapeutics, Inc. ELVN

0000950170-25-071412

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 49.07M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $101.71M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $124.12M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $149.17M
Current Liabilities Q1 2025 · Mar 31, 2025 $13.97M
Current Liabilities Q1 2025 · Dec 31, 2024 $15.92M
Total Liabilities Q1 2025 · Mar 31, 2025 $14.27M
Total Liabilities Q1 2025 · Dec 31, 2024 $15.92M
Current Assets Q1 2025 · Mar 31, 2025 $294.32M
Current Assets Q1 2025 · Dec 31, 2024 $318.13M
Total Assets Q1 2025 · Mar 31, 2025 $302.57M
Total Assets Q1 2025 · Dec 31, 2024 $325.76M
Shares Diluted Q1 2025 · Mar 31, 2024 42.05M sh
Capex Q1 2025 · Mar 31, 2024 $20K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$23.36M
Stockholders Equity Q1 2025 · Mar 31, 2024 $317.71M
Stockholders Equity Q1 2025 · Dec 31, 2023 $245.91M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.54
Eps Basic Q1 2025 · Mar 31, 2024 −$0.54
Sga Expense Q1 2025 · Mar 31, 2024 $6.02M
Rd Expense Q1 2025 · Mar 31, 2024 $19.97M
Net Income Q1 2025 · Mar 31, 2024 −$22.74M
Operating Income Q1 2025 · Mar 31, 2024 −$25.99M